Skip to content
Clinical Trials – home

Azienda Ospedaliera Di Perugia

Verified siteinfo

Italy Piazzale Giorgio Menghini 9, 06129 Perugia, Italy

  • 33 trials recruiting
  • Non-small cell lung cancer · Non-small cell lung cancer metastatic · Neoplasm
  • Adults and children

About Specializations

Azienda Ospedaliera Di Perugia in Perugia, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer metastatic, Neoplasm, Obesity, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Oncology and Lung Cancer Research

At Azienda Ospedaliera Di Perugia, a major focus is respiratory tract diseases, especially non-small cell lung cancer and small cell lung cancer. The trials are exploring new treatment options, combination strategies, and ways to improve outcomes for people with advanced or resectable disease.

  • Advanced and resectable non-small cell lung cancer, including ALK-positive and KRAS G12C-mutated disease
  • Extensive-stage small cell lung cancer in patients with limited health status
  • Studies aimed at testing new therapies, improving survival, and refining treatment choices before or after surgery

This work reflects a strong clinical interest in better targeted care for lung cancer, with several studies also evaluating treatment effectiveness in difficult-to-treat settings.

Hematology and Blood Cancer Trials

The site also supports research in hemic and lymphatic diseases, with trials focused on acute myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia. These studies are designed to assess new anticancer approaches and improve disease control in both newly diagnosed and relapsed settings.

  • Acute myeloid leukemia, including cases with NPM1 mutation or MLL rearrangement
  • Multiple myeloma in patients eligible for transplant
  • Chronic lymphocytic leukemia and small lymphocytic lymphoma after prior treatments

These trials aim to improve response rates, delay progression, and expand options for patients with hard-to-treat blood cancers.

Breast, Kidney, and Other Solid Tumor Studies

Clinical research at the Department of Pneumology also extends to neoplasms beyond lung cancer, including breast cancer, renal cell carcinoma, hepatocellular carcinoma, and selected solid tumors. The main goal is to evaluate better treatment strategies around surgery and systemic therapy.

  • High-risk breast cancer, including hormone receptor-positive disease
  • Renal cell carcinoma with metastatic or oligometastatic spread
  • Advanced liver cancer and other solid tumors requiring improved treatment control

These trials are examining whether new or personalized approaches can improve long-term outcomes and support more effective cancer care.

Cardiovascular Disease and Heart Failure Research

The site has an active portfolio in cardiovascular diseases, including atherosclerotic cardiovascular disease, heart failure, and cardiomyopathy. Research is centered on reducing major cardiac events, improving symptom control, and testing therapies for people at elevated cardiovascular risk.

  • Heart failure with preserved or mildly reduced ejection fraction, often linked with obesity
  • ATTR amyloid cardiomyopathy and related cardiac complications
  • Studies aimed at preventing heart attack, stroke, and other serious vascular events

These trials combine prevention and treatment goals, supporting better management of complex heart conditions in everyday clinical practice.

Immune, Autoimmune, and Transplant-Related Research

Another important area is immune system diseases, with studies in primary Sjögren's syndrome and transplant-related infections or complications. The research is focused on improving symptom control, reducing inflammation, and supporting safer care after stem cell transplant.

  • Primary Sjögren's syndrome and other inflammatory autoimmune conditions
  • Cytomegalovirus infection in hematopoietic stem cell transplant recipients
  • Trials evaluating new anti-inflammatory or antiviral treatment options

These studies aim to make treatment more effective while also improving tolerability in vulnerable patients.

Metabolism, Obesity, and Related Physiological Research

The trial portfolio includes nutritional and metabolic diseases, particularly obesity and overweight without diabetes. The site is also involved in studies of how body weight, metabolism, and related biological processes affect overall health and treatment response.

  • Obesity and overweight management
  • Cell physiological phenomena linked to inflammation and disease activity
  • Research exploring new ways to support weight reduction and improve metabolic health

These trials are designed to test whether emerging therapies can help reduce cardiovascular and metabolic risk in a practical clinical setting.

Neurology, Infectious Disease, and Supportive Care Studies

Beyond cancer and cardiology, the site also contributes to research in nervous system diseases, virus diseases, and supportive care. Current work includes studies in Alzheimer's disease, electrical storm, and respiratory infection-related conditions.

  • Alzheimer's disease and other neurodegenerative conditions
  • Electrical storm requiring urgent rhythm control
  • Bronchiectasis with chronic bacterial colonization and related infection burden

These projects are aimed at improving diagnosis, symptom control, and treatment effectiveness across a broad range of challenging medical conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Piazzale Giorgio Menghini 906129 PerugiaItaly
Recruiting now
33 trials
Conditions studied
49
Partner status
Verified site

More sites in PerugiaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

50 clinical trials

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Eczema nummular

Recruiting

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Neoplasm

Recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Neoplasm

Recruiting

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.